Page 15 of 25
PH6.4 | PH6.4 | Constipation Pharmacotherapy — SDL Guide — SDL Guide (Part 3)
Clinical Decision-Making and Management Plans
A management plan for constipation must integrate aetiology, severity, patient characteristics (age, pregnancy, renal function, comorbidities), and available agents in a stepwise sequence that starts with the safest option and escalates only when needed. The framework below addresses the three most clinically important scenarios: chronic constipation in a general adult, opioid-induced constipation, and constipation in pregnancy — each requiring a distinct pharmacological approach.
General adult chronic constipation (stepwise plan):
Step 1: Lifestyle modification — increase dietary fibre to 25–30 g/day (vegetables, fruit, whole grains), fluid intake 1.5–2 L/day, regular exercise, timed toileting 15–20 minutes after a meal (gastrocolic reflex). This alone resolves 50–60% of functional constipation.
Step 2: First-line pharmacological — bulk-forming laxative (ispaghula) or osmotic laxative (PEG) — safe for chronic use, non-stimulant, non-dependence-forming. Add docusate if stool softening is primarily needed (e.g. post-haemorrhoidectomy, cardiac patient avoiding Valsalva).
Step 3: Short-course stimulant — bisacodyl (oral or suppository for rapid relief) or senna (overnight relief) for acute episodes; not for >2 weeks continuous use.
Step 4: Refractory or IBS-C — linaclotide (IBS-C with abdominal pain: addresses both components) or lubiprostone (chronic idiopathic constipation); prucalopride (slow-transit constipation unresponsive to conventional laxatives).
Opioid-induced constipation (OIC):
OIC is caused by mu-opioid receptor activation in the enteric nervous system and is highly resistant to conventional laxatives because the causative receptor mechanism is not addressed. Standard approach: PEG or lactulose as osmotic backbone + docusate to soften stools. If inadequate after optimising doses → add methylnaltrexone (subcutaneous injection, 8–12 mg depending on weight, given every other day) or naloxegol (oral PAMORA, 25 mg once daily). Both are peripherally acting mu-opioid antagonists (PAMORAs) that block gut opioid receptors without crossing the BBB → no analgesic reversal. Contraindicated if bowel obstruction is suspected.
Constipation in pregnancy:
- Safe: Ispaghula (bulk-forming — not absorbed, no fetal risk), lactulose (non-absorbed), docusate.
- PEG: Generally considered safe; limited data but widely used.
- Bisacodyl/senna: Caution — occasional short-course use probably safe; avoid in first trimester and near term (theoretical uterotonic concern with anthraquinones at high doses).
- Avoid: Castor oil (uterotonic — induces labour), cascara (large amounts may cause neonatal diarrhoea via breast milk), liquid paraffin (aspiration risk, vitamin malabsorption).
- First-line in pregnancy: ispaghula + lactulose; PEG if insufficient.
| Clinical context | First-line | Add if insufficient | Avoid |
|---|---|---|---|
| Chronic constipation (adult) | Ispaghula + lifestyle / PEG | Bisacodyl short-course | Liquid paraffin (chronic use) |
| IBS-C | Linaclotide or lubiprostone | — | — |
| Opioid-induced | PEG + docusate | PAMORA (methylnaltrexone) | Stimulants alone |
| Pregnancy | Ispaghula + lactulose | PEG | Castor oil, high-dose stimulants |
| Acute evacuation (e.g., pre-procedure) | Bisacodyl suppository or PEG (bowel prep) | — | — |
CLINICAL PEARL
Melanosis coli — a benign but informative endoscopic finding:
Melanosis coli is brown-black discolouration of the colonic mucosa seen at colonoscopy in patients who have used anthraquinone laxatives (senna, cascara) long-term. It results from accumulation of lipofuscin-laden macrophages in the lamina propria — the macrophages have phagocytosed apoptotic colonic epithelial cells damaged by anthranols. Melanosis coli is entirely benign and reversible within 4–12 months of stopping the anthraquinone laxative. However, its presence at colonoscopy immediately tells the endoscopist that the patient has been using senna/cascara regularly — a pharmacological history revealed by endoscopy. This illustrates that drug use leaves a biological signature that physicians can recognise. From a clinical perspective, melanosis coli also raises the question of whether the patient has developed laxative dependence — the enteric neuropathy hypothesis suggests prolonged stimulant laxative use may reduce the intrinsic peristaltic drive, making spontaneous bowel movements more difficult. While this hypothesis remains debated, the pragmatic clinical recommendation is: limit stimulant laxatives to short courses, and transition patients on chronic senna to safer long-term alternatives (PEG, psyllium).
Self-Assessment — Constipation Pharmacotherapy
The self-assessment scenarios below test your pharmacological reasoning in three high-yield constipation contexts: a pregnancy-related case (choosing safe vs unsafe laxatives), an IBS-C case (selecting the agent that addresses both constipation and visceral pain), and a drug-interaction scenario (bisacodyl and antacids). For each, work through the mechanism before examining the answer options. Mechanistic reasoning ensures that you will handle novel variants of the same clinical question correctly; memorisation of drug names alone will fail when the clinical details change. Pay particular attention to the IBS-C scenario, where the dual pro-secretory and analgesic mechanism of linaclotide is the defining distinguishing feature — this is one of the newer mechanisms that Year-2 students are expected to understand.
The self-assessment scenarios below test your pharmacological reasoning in three high-yield constipation contexts: a pregnancy-related case (choosing safe vs unsafe laxatives), an IBS-C case (selecting the agent that addresses both constipation and pain), and a drug-interaction scenario (bisacodyl and antacids). For each, work through the mechanism before looking at the options. A correct answer based on mechanism means you will handle novel variants of the same clinical question correctly; a correct answer based on memorisation may fail when the clinical details are changed slightly.
Work through the micro-quiz below before reviewing the explanations.
SELF-CHECK
A 38-year-old woman has IBS-C with significant abdominal cramping and fewer than 2 spontaneous complete bowel movements per week. She has failed a 3-month trial of ispaghula and PEG. Which agent addresses BOTH her constipation AND her visceral pain?
A. Senna 2 tablets at night — stimulates bowel movements
B. Bisacodyl suppository — rapid relief of constipation
C. Linaclotide — GC-C agonist that increases stool secretion and reduces visceral pain afferents
D. Lubiprostone — ClC-2 activator that softens stool
Reveal Answer
Answer: C. Linaclotide — GC-C agonist that increases stool secretion and reduces visceral pain afferents
Linaclotide is the correct choice for IBS-C with both constipation and abdominal pain. Its mechanism is dual: (1) it activates GC-C receptors on intestinal epithelial cells → increased cGMP → CFTR activation → Cl- and water secretion into the lumen → softer, more frequent stools; (2) cGMP generated in the epithelium diffuses to subepithelial sensory neurones and inhibits visceral pain-sensing (specifically, reduces sodium channel-dependent pain signalling from the gut). This dual pro-secretory + analgesic action is what distinguishes linaclotide from senna or bisacodyl (which only promote defaecation without addressing pain) and from lubiprostone (which promotes secretion via ClC-2 but has a less established pain-reducing effect). Lubiprostone is preferred for chronic idiopathic constipation rather than IBS-C with prominent pain.